Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 11/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 4/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29403117 | 0.94 | DDB1 (0.55) | DDB1CRBNPOLBDRD4DRD2 | |
| SCHEMBL22118175 | 0.94 | DDB1 (0.55) | DDB1CRBNPOLBDRD4DRD2 | |
| Hydrochloric Acid SCHEMBL22117971 | 0.93 | DDB1 (0.54) | DDB1CRBNPOLBDRD4DRD2 | |
| Hydrochloric Acid SCHEMBL31174905 | 0.93 | DDB1 (0.54) | DDB1CRBNPOLBDRD4DRD2 | |
| SCHEMBL24161552 | 0.85 | DDB1 (0.67) | DDB1CRBNPOLBALDH1A1CYP2D6 | |
| SCHEMBL31447686 | 0.83 | DDB1 (0.71) | DDB1CRBN | |
| SCHEMBL22117961 | 0.83 | DDB1 (0.55) | DDB1CRBNPOLBDRD4DRD2 | |
| SCHEMBL22128953 | 0.83 | DDB1 (0.55) | DDB1CRBNPOLBDRD4DRD2 | |
| SCHEMBL31447911 | 0.83 | DDB1 (0.50) | DDB1CRBN | |
| SCHEMBL24290129 | 0.83 | DDB1 (0.52) | DDB1CRBNPOLBDRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | claimed |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | DDB1 1245/4885CRBN 324/4885POLB 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.